Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
DalCor Pharmaceuticals (Canada)
Homepage:
dalcorpharma.com
Alternate names:
DalCor Pharmaceuticals,
DalCor Pharmaceuticals Canada Inc.
ROR:
00m33qn53
OpenAlex ID:
I4405270399
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
2022
·
Kausik K Ray
, Frederick J Raal
, et al.
·
European Heart Journal
·
248
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
2022
·
Kausik K Ray
, David Kallend
, et al.
·
European Heart Journal
·
121
PDF
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
2022
·
Jean Claude Tardif
, Marc A Pfeffer
, et al.
·
European Heart Journal
·
40
PDF
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib
2020
·
Jean-Claude Tardif
, Marie-Pierre Dubé
, et al.
·
American Heart Journal
·
30
PDF
Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
2021
·
Eric J Niesor
, Guy Boivin
, et al.
·
ACS Omega
·
23
Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials
2021
·
W Koenig
, K K Ray
, et al.
·
European Heart Journal
·
3
PDF
Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials
2021
·
W Koenig
, K K Ray
, et al.
·
European Heart Journal
·
2
PDF
Effect of inclisiran on haematological and immunological biomarkers: A Pooled analysis of ORION-9, -10 and -11 trial data
2021
·
U. Landmesser
, L. Garcia Conde
, et al.
·
Atherosclerosis
·
2
Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib
2025
·
Jean-Claude Tardif
, Marc A Pfeffer
, et al.
·
European Journal of Preventive Cardiology
·
1
PDF
Challenges of the allosteric regulation of hemoglobin by interaction with Cys93 of the β chain for the treatment of sickle cell disease
2025
·
Eric Joseph Niesor
, Anne Perez
, et al.
·
Journal of sickle cell disease.
·
1
PDF
Efficacy and Safety of Inclisiran by Baseline Body Mass Index: a Post Hoc Pooled Analysis of the Orion-9, Orion-10 and Orion-11 Phase Iii Randomized Controlled Trials
2023
·
Lawrence A Leiter
, David G Kallend
, et al.
·
American Journal of Preventive Cardiology
·
1
459 Evaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither
2021
·
R. Scott Wright
, David Kallend
, et al.
·
European Heart Journal Supplements
·
1
PDF
Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia
2020
·
F.J. Raal
, D. Kallend
, et al.
·
Atherosclerosis
·
1
Abstract 11033: Efficacy and Safety of Inclisiran by Baseline Glycemic Status: A Post Hoc Pooled Analysis of the ORION-10 and ORION-11 Phase III Randomized Controlled Trials
2021
·
Lawrence A Leiter
, David G Kallend
, et al.
·
Circulation
Abstract 11143: Efficacy and Safety of Inclisiran by Baseline Body Mass Index: A Post Hoc Pooled Analysis of the ORION-9, ORION-10 and ORION-11 Phase III Randomized Controlled Trials
2021
·
Lawrence A Leiter
, David G Kallend
, et al.
·
Circulation
Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: analysis from the phase III ORION-11 trial
2020
·
K.K. Ray
, D. Kallend
, et al.
·
Atherosclerosis
P6193Dalcetrapib reduces incident diabetes in patients with recent acute coronary syndrome
2019
·
G Schwartz
, L A Leiter
, et al.
·
European Heart Journal
Show more works
View as search
Works count:
17
Citation count:
609
Year
Topic
Type
